ong-term outcomes and predictive factors for survival in premenopausal breast cancer treated with tamoxife

Not Applicable

• Conditions: Premenopausal patients with invasive breast cancer; Cancer; Malignant neoplasm of breast

• Registration Number: ISRCTN12474687
• Lead Sponsor: und University

Brief Summary

2020 Interim results article in https://pubmed.ncbi.nlm.nih.gov/33357231/ results on predictive value of tumour-infiltrating lymphocytes (added 29/12/2020) 2022 Interim results article in https://pubmed.ncbi.nlm.nih.gov/35534504/ PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients (added 10/05/2022) 2023 Interim results article in https://pubmed.ncbi.nlm.nih.gov/37773134/ Relationship between tamoxifen treatment and breast cancer gene expression (added 02/10/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-12-06
• Last Update Posted: 16 October 2023
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: Female
• Target Recruitment: 564

Inclusion Criteria

Patients radically operated for invasive breast cancer stage II in the SBII:2 trial

Exclusion Criteria

1. Postmenopausal status
2. Metastatic disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BCFi (Breast cancer free interval) over the ~30-year period, measured using patient notes

Secondary Outcome Measures

Name	Time	Method
1. D-RFi (Distant Recurrence Free interval) over the ~30-year period, measured using patient notes<br>2. Breast cancer mortality over the ~30-year period, measured using patient notes<br>3. Overall mortality over the ~30-year period, measured using patient notes